secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProMIS Neurosciences Inc. (PMN)
CIK:        0001374339
Form:       8-K
Filed at:   2026-03-25T23:59:59+00:00
Accession:  0001104659-26-034162
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProMIS Neurosciences reports FY2025 net loss of $39.7M; Phase 1b fully enrolled, $75.5M financing closed
--------------------------------------------------------------------------------

- Net loss of $39.7M in FY2025; R&D expense soared to $33.4M from $10.6M a year ago, driven by PRECISE-AD trial.
- Cash of $6.1M at Dec 31, 2025; subsequent $75.5M private placement in Feb 2026 provides cash runway through 2027.
- PRECISE-AD Phase 1b enrollment completed with 144 patients; six-month blinded interim data expected early Q3 2026.
- PMN310 continues to show favorable safety profile with no treatment-related SAEs reported after over 12 months of dosing.
- PMN310 granted FDA Fast Track Designation in July 2025; goal to advance directly into a single registrational study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374339/000110465926034162/0001104659-26-034162-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374339/000110465926034162/pmn-20260325x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-034162

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer